Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Studies show that patients who are obese or overweight using injectable GLP-1 agonist medications for weight loss, combined with diet and exercise, achieve weight loss of approximately 6% of their body weight at 4 months, 9% at 6 months, and 13% at 12 months
Mail-order Pharmacy Fulfillment To complete the circle of care, WellSync integrates mail-order pharmacy fulfillment into the GLP-1 prescription program
Tirzepatide was developed as a unimolecular dual agonist and moved through the SURPASS (type 2 diabetes) and SURMOUNT (obesity) Phase 3 programs to approval, becoming the first approved GLP-1/GIP dual agonist
The woman enrolled in a small trial at Penn that involved using NAc-focused electrical stimulation to help ease food noise in the brain
Ongoing Care and Support Our commitment to our patients extends beyond the treatment sessions
US$ 26.65
US$ 23.00
US$ 29.49
US$ 27.81
US$ 28.63
